Related Content
- Medication adherence could be blockbuster for specialty
- Adherence is boosted by face-to-face contact, study finds
- Adherence among chronic disease patients can lead to big savings
- PhRMA: Nearly 300 preventive medicines for heart disease, stroke in development
- Bartell to cease filling Medicaid prescriptions at 15 locations
NEW YORK — Teva Pharmaceuticals USA will delay the sales of generic versions of two Gilead Sciences HIV drugs until June 2013, the company stated. The decision comes pending a long-running patent suit in the U.S. District Court for the Southern District of New York.
Teva may launch generics for Truvada (i.e., emtricitabine/tenofovir disoproxil fumarate) and Viread (i.e., tenofovir disoproxil fumarate) on June 1 if there is no ruling holding that the patents-in-suit are invalid or unenforceable, according to an agreement filed between the drug makers Nov. 27.
The case, Gilead Sciences v. Teva Pharmaceuticals USA, et al. is set for trial on Feb. 20, 2013.
